Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/Esketamine/Immunology & Inflammation

Esketamine for Immunology & Inflammation

3 papers and 1 clinical trial exploring esketamine as a treatment for immunology & inflammation.

Compounddissociative

Esketamine

Esketamine (Spravato) is the S-enantiomer of ketamine, approved as an intranasal treatment for treatment-resistant depression and MDD with acute suicidal ideation. It is administered under clinical supervision with post-dose monitoring and has reached over $1.6 billion in annual sales.

Full Esketamine profile
IndicationOver 264 million people worldwide suffer from depression, with a significant subset experiencing related inflammatory conditions.

Immunology & Inflammation

Recent research highlights the potential of psychedelics, particularly psilocybin and MDMA, in modulating immune responses and inflammation, shedding light on their therapeutic implications for mood disorders and other immune-related conditions. Studies are beginning to uncover the mechanisms through which these compounds exert anti-inflammatory effects and promote neuroplasticity, particularly in the context of major depressive disorder (MDD).

Full Immunology & Inflammation profile

Academic Research

3 papers
Paywallmeta

Blood-based biomarkers of antidepressant response to ketamine and esketamine: A systematic review and meta-analysis

This meta-analysis (n=2,801) explored the association between baseline levels and longitudinal changes in blood-based biomarkers, and response to ketamine/esketamine. Over 460 individual biomarkers were examined and there were no consistent associations between baseline levels of blood-based biomarkers, and response to ketamine. However, a longitudinal analysis revealed ketamine responders had statistically significant increases in brain-derived neurotrophic factor (BDNF) when compared to pre-treatment.

Published
June 27, 2022
Journal
Molecular Psychiatry
Authors
Medeiros, G. C., Gould, T. D., Prueitt, W. L., Nanavati, J., Grunebaum, M. F., Farber, N. B., Singh, B., Selvaraj, S., Machado-Vieira, R., Achtyes, E. D., Parikh, S. V., Frye, M. A., Zarate, C. A., Goes, F. S.
Paywallmeta

Ketamine for suicidality: an umbrella review

This review (2022) investigated the role of ketamine in suicidal ideation (SI) and behaviours. Of 27 studies that addressed ketamine for SI, only four reported mixed or negative results. Out of nine reviews, esketamine was significantly beneficial in five. Despite the majority of reviews being of critically low quality, the short-term efficacy of ketamine in suicidality was noted in most.

Published
April 21, 2022
Journal
British Journal of Clinical Pharmacology
Authors
Shamabadi, A., Ahmadzade, A., Hasanzadeh, A.
Open Accessindividual

Absence of long-term analgesic effect from a short-term S-ketamine infusion on fibromyalgia pain: A randomized, prospective, double blind, active placebo-controlled trial

In a randomised, double-blind, active placebo-controlled trial of 24 fibromyalgia patients, a 30‑minute S‑ketamine infusion produced transient pain reductions that closely tracked plasma levels but yielded no significant long-term analgesic benefit over an eight‑week follow‑up versus midazolam. Side effects were mild–moderate and declined rapidly, suggesting adequate blinding.

Published
January 13, 2012
Journal
European Journal of Pain
Authors
Noppers, I., Niesters, M., Swartjes, M., Bauer, M., Aarts, L., Geleijnse, N., Mooren, R., Dahanl, A., Sarton, E.

Clinical Trials

1 trial
RecruitingPhase NA

Study of the Neural Circuits Underlying the Negative Emotional Bias of Depressive Disorders and Their Response to Ketamine (EMOKET)

Open-label interventional parallel study (n=96) comparing depressed patients treated with esketamine (Spravato) with healthy volunteers using fMRI emotional tasks, behavioural measures and biological profiling.

Started
March 13, 2023
Type
interventional
Blinding
none
Randomized
No
Registry ID
NCT06630065

Explore further

Search all Esketamine papers Search all Immunology & Inflammation trials Full Esketamine profile Full Immunology & Inflammation profile